Published in Diabetes Care on September 09, 2008
Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA (2014) 4.50
Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care (2010) 3.68
Cost-effectiveness of self-monitoring of blood glucose in patients with type 2 diabetes mellitus managed without insulin. CMAJ (2009) 2.70
Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care (2011) 2.54
Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care (2013) 2.33
Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis. Open Med (2011) 1.41
Metformin initiation and renal impairment: a cohort study in Denmark and the UK. BMJ Open (2015) 1.38
Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012. Diabetes Care (2013) 1.32
Metformin attenuates Alzheimer's disease-like neuropathology in obese, leptin-resistant mice. Pharmacol Biochem Behav (2012) 1.20
Severe hypoglycemia symptoms, antecedent behaviors, immediate consequences and association with glycemia medication usage: Secondary analysis of the ACCORD clinical trial data. BMC Endocr Disord (2012) 1.03
Hypoglycaemia and accident risk in people with type 2 diabetes mellitus treated with non-insulin antidiabetes drugs. Diabetes Obes Metab (2012) 1.03
Metformin efficacy and safety for colorectal polyps: a double-blind randomized controlled trial. BMC Cancer (2012) 1.01
Hypoglycemia in type 2 diabetes: current controversies and changing practices. Front Endocrinol (Lausanne) (2012) 0.95
Metformin in chronic kidney disease: time for a rethink. Perit Dial Int (2014) 0.95
Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab (2015) 0.93
Metformin--an adjunct antineoplastic therapy--divergently modulates tumor metabolism and proliferation, interfering with early response prediction by 18F-FDG PET imaging. J Nucl Med (2013) 0.89
The Discovery of MK-4256, a Potent SSTR3 Antagonist as a Potential Treatment of Type 2 Diabetes. ACS Med Chem Lett (2012) 0.88
Association of hypoglycemic symptoms with patients' rating of their health-related quality of life state: a cross sectional study. Health Qual Life Outcomes (2010) 0.87
Does metformin affect the incidence of colonic polyps and adenomas in patients with type 2 diabetes mellitus? Intest Res (2014) 0.83
Management of type 2 diabetes mellitus in older patients: current and emerging treatment options. Diabetes Ther (2013) 0.83
Pharmacodynamics of the glucagon-like peptide-1 receptor agonist lixisenatide in Japanese and Caucasian patients with type 2 diabetes mellitus poorly controlled on sulphonylureas with/without metformin. Diabetes Obes Metab (2014) 0.83
Changes in prescribing patterns and clinical outcomes in elderly diabetic patients in 2000 and 2010: analysis of a large Italian population-based study. Eur J Clin Pharmacol (2014) 0.81
Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus. BMC Pharmacol Toxicol (2013) 0.81
Risks of Metformin in Type 2 Diabetes and Chronic Kidney Disease: Lessons Learned from Taiwanese Data. Nephron (2016) 0.81
Cost-effectiveness of blood glucose test strips in the management of adult patients with diabetes mellitus. CADTH Technol Overv (2010) 0.80
Medication safety and chronic kidney disease in older adults prescribed metformin: a cross-sectional analysis. BMC Nephrol (2014) 0.80
Changes in labelling for metformin use in patients with type 2 diabetes and heart failure: documented safety outweighs theoretical risks. Open Med (2011) 0.79
Diabetes mellitus and renal failure: Prevention and management. J Res Med Sci (2015) 0.79
Anti-hyperglycemic activity of Centella asiatica is partly mediated by carbohydrase inhibition and glucose-fiber binding. BMC Complement Altern Med (2014) 0.79
Cost implications to health care payers of improving glucose management among adults with type 2 diabetes. Health Serv Res (2011) 0.79
The effects of quality of care on costs: a conceptual framework. Milbank Q (2013) 0.78
Use of Metformin in Patients with Kidney and Cardiovascular Diseases. Cardiorenal Med (2011) 0.78
Comparison of clinical characteristics in patients with type 2 diabetes among whom different antihyperglycemic agents were prescribed as monotherapy or combination therapy by diabetes specialists. J Diabetes Investig (2015) 0.78
Lactic Acidosis in a Patient with Type 2 Diabetes Mellitus. Clin J Am Soc Nephrol (2015) 0.78
Metformin and cancer: Quo vadis et cui bono? Oncotarget (2016) 0.78
Metformin in peritoneal dialysis: a pilot experience. Perit Dial Int (2014) 0.78
Association between Use of Oral Anti-Diabetic Drugs and the Risk of Sepsis: A Nested Case-Control Study. Sci Rep (2015) 0.77
Medicinal Plants Qua Glucagon-Like Peptide-1 Secretagogue via Intestinal Nutrient Sensors. Evid Based Complement Alternat Med (2015) 0.77
Discovery and Optimization of a Novel Triazole Series of GPR142 Agonists for the Treatment of Type 2 Diabetes. ACS Med Chem Lett (2016) 0.75
Comparison of baseline characteristics and clinical course in Japanese patients with type 2 diabetes among whom different types of oral hypoglycemic agents were chosen by diabetes specialists as initial monotherapy (JDDM 42). Medicine (Baltimore) (2017) 0.75
Sulfonylurea use and the risk of hospital readmission in patients with type 2 diabetes. BMC Endocr Disord (2016) 0.75
Safety and effectiveness of insulin detemir in different age-groups in the a1chieve study. Diabetes Ther (2013) 0.75
Lactic Acidosis in Diabetic Population: Is Metformin Implicated? Results of a Matched Case-Control Study Performed on the Type 2 Diabetes Population of Grenoble Hospital University. J Diabetes Res (2016) 0.75
Metformin therapy and the risk of colorectal adenoma in patients with type 2 diabetes: A meta-analysis. Oncotarget (2016) 0.75
Association between Metformin Use and Risk of Lactic Acidosis or Elevated Lactate Concentration in Type 2 Diabetes. Yonsei Med J (2017) 0.75
Effect of sericin on diabetic hippocampal growth hormone/insulin-like growth factor 1 axis. Neural Regen Res (2013) 0.75
Provider Decisions and Patient Outcomes After Premature Metformin Discontinuation. Diabetes Spectr (2017) 0.75
Lactic acidosis and the relationship with metformin usage: Case reports. Medicine (Baltimore) (2016) 0.75
Effect of prescribing metformin according to eGFR instead of serum creatinine level: A study based on Korean National Health and Nutrition Examination Survey (KNHANES) 2009-2014. PLoS One (2017) 0.75
Efficacy and safety of fixed-dose combination therapy alogliptin plus metformin in Asian patients with type 2 diabetes: a phase 3 trial. Diabetes Obes Metab (2017) 0.75
Changes in metformin use in chronic kidney disease. Clin Kidney J (2017) 0.75
Berberine protects against metformin-associated lactic acidosis in induced diabetes mellitus. Iran J Basic Med Sci (2017) 0.75
Metformin Safety Warnings and Diabetes Drug Prescribing Patterns for Older Nursing Home Residents. J Am Med Dir Assoc (2017) 0.75
Lactate Levels with Chronic Metformin Use: A Narrative Review. Clin Drug Investig (2017) 0.75
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet (1998) 34.34
Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ (1991) 17.91
Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol (1998) 7.41
Validity of the general practice research database. Pharmacotherapy (2003) 6.78
Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med (2007) 6.09
Lactic acidosis rates in type 2 diabetes. Diabetes Care (1998) 3.40
Use of thiazolidinediones and fracture risk. Arch Intern Med (2008) 2.99
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med (2003) 2.90
Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med (2001) 2.64
The general practice research database: role in pharmacovigilance. Drug Saf (2004) 2.38
Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med (1998) 2.26
Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents. Diabetes Care (1989) 2.07
Incidence of lactic acidosis in metformin users. Diabetes Care (1999) 1.81
Lactic acidosis in metformin-treated patients. Prognostic value of arterial lactate levels and plasma metformin concentrations. Drug Saf (1999) 1.69
Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications. Eur J Intern Med (2002) 1.44
Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated? BMJ (2007) 1.34
Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes. Exp Clin Endocrinol Diabetes (2003) 1.29
Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol (1997) 1.27
Metformin-associated lactic acidosis in patients with renal impairment solely due to drug accumulation? Diabetes Obes Metab (2008) 1.03
Consequences of metformin intoxication. Diabetes Care (1998) 0.93
Severe hypoglycemia and smoking in a long-term type 1 diabetic population: Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetes Care (2007) 0.92
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev (2003) 0.85
Antidepressants and the risk of suicidal behaviors. JAMA (2004) 7.08
Validity of the general practice research database. Pharmacotherapy (2003) 6.78
Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care (2010) 3.68
Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. Neurology (2004) 3.21
Use of thiazolidinediones and fracture risk. Arch Intern Med (2008) 2.99
Opioid pharmacotherapy for chronic non-cancer pain in the United States: a research guideline for developing an evidence-base. J Pain (2010) 2.90
Cardiovascular flow measurement with phase-contrast MR imaging: basic facts and implementation. Radiographics (2002) 2.89
Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials. Am Heart J (2006) 2.87
Drug-related problems in hospitals: a review of the recent literature. Drug Saf (2007) 2.80
Development and evaluation of a quality-controlled ribosomal sequence database for 16S ribosomal DNA-based identification of Staphylococcus species. J Clin Microbiol (2004) 2.59
Use of antihypertensives and the risk of Parkinson disease. Neurology (2008) 2.51
Statin use and risk of gallstone disease followed by cholecystectomy. JAMA (2009) 2.31
Testosterone lab testing and initiation in the United Kingdom and the United States, 2000 to 2011. J Clin Endocrinol Metab (2014) 2.18
Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction. Am J Cardiol (2004) 2.11
Hepatitis B vaccination and multiple sclerosis: the jury is still out. Pharmacoepidemiol Drug Saf (2006) 2.06
Prospective study of the spontaneous course of subclinical hypothyroidism: prognostic value of thyrotropin, thyroid reserve, and thyroid antibodies. J Clin Endocrinol Metab (2002) 1.94
Hepatotoxicity during rapid intravenous loading with amiodarone: Description of three cases and review of the literature. Crit Care Med (2005) 1.77
The human brain endothelial cell line hCMEC/D3 as a human blood-brain barrier model for drug transport studies. J Neurochem (2008) 1.66
Statins and the risk of idiopathic venous thromboembolism. Br J Clin Pharmacol (2002) 1.65
Psoriasis and risk of incident cancer: an inception cohort study with a nested case-control analysis. J Invest Dermatol (2009) 1.62
Statins and the risk of pneumonia: a population-based, nested case-control study. Pharmacotherapy (2007) 1.61
Use of beta-blockers and risk of fractures. JAMA (2004) 1.58
Elevated C-reactive protein and homocysteine values: cardiovascular risk factors in hypothyroidism? A cross-sectional and a double-blind, placebo-controlled trial. Atherosclerosis (2003) 1.55
Cigarette smoking and the progression of multiple sclerosis. Brain (2005) 1.52
Tamoxifen-treated breast carcinoma patients and the risk of acute myocardial infarction and newly-diagnosed angina. Cancer (2005) 1.50
Acute mycophenolate overdose: case series and systematic literature analysis. Expert Opin Drug Saf (2014) 1.48
Antibiotic use and risk of multiple sclerosis. Am J Epidemiol (2006) 1.45
Use of metformin is not associated with a decreased risk of colorectal cancer: a case-control analysis. Cancer Epidemiol Biomarkers Prev (2011) 1.44
Diabetes mellitus and the risk of cholecystectomy. Dig Liver Dis (2011) 1.44
Incidence of the pneumoconioses in the United Kingdom general population between 1997 and 2008. Respiration (2012) 1.41
Statin use and risk of first-time psoriasis diagnosis. J Am Acad Dermatol (2011) 1.41
Chronic obstructive pulmonary disease and the risk of cardiovascular diseases. Eur J Epidemiol (2010) 1.41
Association of infant pneumococcal vaccination with pneumococcal pneumonia among mothers: a nested case-control study using the GPRD. Vaccine (2013) 1.40
Using prescription claims data for drugs available over-the-counter (OTC). Pharmacoepidemiol Drug Saf (2007) 1.39
Use of metformin and the risk of ovarian cancer: a case-control analysis. Gynecol Oncol (2011) 1.38
Use of nonsteroidal anti-inflammatory drugs and the risk of first-time acute myocardial infarction. Br J Clin Pharmacol (2002) 1.30
Recent use of oral contraceptives and the risk of multiple sclerosis. Arch Neurol (2005) 1.27
Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis. Am J Gastroenterol (2012) 1.27
Dose adjustment in patients with liver disease. Drug Saf (2005) 1.26
Current use of selective serotonin reuptake inhibitors and risk of acute myocardial infarction. Drug Saf (2004) 1.25
COPD and the risk of depression. Chest (2009) 1.23
Drug interactions and risk of acute bleeding leading to hospitalisation or death in patients with chronic atrial fibrillation treated with warfarin. Thromb Haemost (2005) 1.23
Metformin, other antidiabetic drugs, and risk of Alzheimer's disease: a population-based case-control study. J Am Geriatr Soc (2012) 1.22
Automated HPLC assay for urinary collagen cross-links: effect of age, menopause, and metabolic bone diseases. Clin Chem (2008) 1.19
Prevalence of drug-drug interactions at hospital entry and during hospital stay of patients in internal medicine. Eur J Intern Med (2008) 1.18
Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from the UK General Practice Research Database. Br J Clin Pharmacol (2005) 1.17
Metformin does not alter the risk of lung cancer: a case-control analysis. Lung Cancer (2012) 1.17
Mechanisms of benzarone and benzbromarone-induced hepatic toxicity. Hepatology (2005) 1.15
Benzodiazepine prescribing to the Swiss adult population: results from a national survey of community pharmacies. Int Clin Psychopharmacol (2007) 1.14
Duloxetine inhibits effects of MDMA ("ecstasy") in vitro and in humans in a randomized placebo-controlled laboratory study. PLoS One (2012) 1.13
Patient-related risk factors for fracture-healing complications in the United Kingdom General Practice Research Database. Acta Orthop (2012) 1.12
Regulation of BCRP (ABCG2) and P-glycoprotein (ABCB1) by cytokines in a model of the human blood-brain barrier. Cell Mol Neurobiol (2009) 1.11
The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med (2010) 1.10
Systematic review of medication safety assessment methods. Am J Health Syst Pharm (2011) 1.08
Parathyroid hormone analogues in the treatment of osteoporosis. Nat Rev Endocrinol (2011) 1.07
Age-related changes in serum testosterone and sex hormone binding globulin in Australian men: longitudinal analyses of two geographically separate regional cohorts. J Clin Endocrinol Metab (2007) 1.07
Rhabdomyolysis in association with simvastatin and amiodarone. Ann Pharmacother (2004) 1.06
Surgical Timing and the Menstrual Cycle Affect Wound Healing in Young Breast Reduction Patients. Plast Reconstr Surg (2016) 1.06
The risk of severe depression, psychosis or panic attacks with prophylactic antimalarials. Drug Saf (2004) 1.05
The prevalence of potential drug-drug interactions in patients with heart failure at hospital discharge. Drug Saf (2006) 1.04
Evaluation of frequently used drug interaction screening programs. Pharm World Sci (2008) 1.03
Prevalence of potentially inappropriate medication use in elderly patients: comparison between general medical and geriatric wards. Drugs Aging (2006) 1.03
Risk for incident atrial fibrillation in patients who receive antihypertensive drugs: a nested case-control study. Ann Intern Med (2010) 1.03
Trends in incidence and medical resource utilisation in patients with chronic lymphocytic leukaemia: insights from the UK Clinical Practice Research Datalink (CPRD). Ann Hematol (2014) 1.02
Use of statins and the risk of Parkinson's disease: a retrospective case-control study in the UK. Drug Saf (2008) 1.02
Characterization of the membrane-destabilizing properties of different pH-sensitive methacrylic acid copolymers. Biochim Biophys Acta (2003) 1.01
Diabetes in patients with idiopathic Parkinson's disease. Diabetes Care (2008) 1.01
Appropriateness of serum level determinations of antiepileptic drugs. Swiss Med Wkly (2003) 1.01
Age-related differences in the prevalence of potential drug-drug interactions in ambulatory dyslipidaemic patients treated with statins. Drugs Aging (2007) 1.00
Discontinuation of nonsteroidal anti-inflammatory drug therapy and risk of acute myocardial infarction. Arch Intern Med (2004) 1.00
Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping. Br J Clin Pharmacol (2008) 1.00